Last reviewed · How we verify
BMS-708163
BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease.
BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease. Used for Alzheimer's disease.
At a glance
| Generic name | BMS-708163 |
|---|---|
| Also known as | (GAMMA SECRETASE inhibitor) |
| Sponsor | Bristol-Myers Squibb |
| Drug class | BACE inhibitor |
| Target | BACE1 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting BACE1, BMS-708163 reduces the cleavage of amyloid precursor protein (APP) into amyloid-beta peptides, potentially slowing the progression of Alzheimer's disease.
Approved indications
- Alzheimer's disease
Common side effects
- Headache
- Diarrhea
Key clinical trials
- A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease (PHASE2)
- A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
- Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163 (PHASE1)
- Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 (PHASE1)
- Drug-Drug Interaction Study With Rifampin (PHASE1)
- Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole (PHASE1)
- Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) (PHASE1)
- Drug-Drug Interaction Study With Aricept® (Donepezil) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |